Septerna stock: recent moves and what they might mean for investors

Septerna (SEPN) has attracted attention after a month return of about 24% and a past 3 months return above 10%, prompting investors to reassess how its clinical-stage biotech profile aligns with this recent share performance.

The recent 24.3% 1 month share price return, alongside a 10.9% 3 month share price return and a very large 1 year total shareholder return, suggests momentum has been building as investors reassess Septerna’s clinical pipeline and risk profile at around US$29.02 per share.

If Septerna’s move has you looking beyond a single biotech name, this could be a good moment to scan 28 healthcare AI stocks for other healthcare names tied to advanced data and AI driven therapies.

With the share price at about US$29.02 and a very large 1 year total return already on the table, you have to ask yourself: is Septerna still undervalued, or is the market already pricing in future growth?

Preferred Price-to-Book of 3.3x: Is it justified?

At a last close of about $29.02, Septerna is trading on a P/B of 3.3x, which screens as expensive against the broader US Pharmaceuticals industry but cheaper than its closest peer set.

P/B compares the market value of the company to its net assets on the balance sheet. This ratio is often a reference point for clinical stage biotech where earnings are still negative and traditional P/E is less useful. A higher P/B can reflect optimism around the pipeline, expected future cash flows, or the value investors place on the underlying GPCR platform rather than current profits.

For Septerna, the 3.3x P/B sits above the US Pharmaceuticals industry average of 2.2x, so the market is paying a higher price for each dollar of book value than for the typical company in the sector. However, that same 3.3x is below the 4.1x average for closer peers. This suggests investors are assigning a smaller premium than to some comparable names even though Septerna is still loss making and reported a net loss of $58.809m against revenue of $22.045m.

The spread between 3.3x and the industry average 2.2x is wide. This implies the market is already assigning extra value to Septerna's recent revenue performance, including its very large 1 year revenue increase and forecast revenue growth of 10.49% per year, while still discounting it relative to peer valuations at 4.1x.

Result: Price-to-book of 3.3x (OVERVALUED)

However, you also need to weigh clinical and regulatory uncertainty around Septerna’s GPCR programs alongside ongoing net losses of $58.809m on revenue of $22.045m.

Next Steps

Given the mix of enthusiasm and caution around Septerna, it makes sense to look at the numbers yourself and decide how you feel about the balance of risk and reward. To see how that trade off looks in detail, take a closer look at 2 key rewards and 2 important warning signs.

Looking for more investment ideas?

If Septerna has sharpened your focus, do not stop here. Use the Simply Wall St screener to quickly spot other opportunities that match what you care about.

• Target value by reviewing our list of 49 high quality undervalued stocks that combine quality fundamentals with pricing that might still leave room on the table.
• Prioritise resilience with 76 resilient stocks with low risk scores, so you are not missing companies where our risk checks flag fewer warning signs.
• Get ahead of the crowd by scanning the screener containing 24 high quality undiscovered gems that pass fundamental filters yet are not widely followed.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.